Denali Therapeutics Inc (NASDAQ:DNLI)
| 31.38 Delayed Data As of 3:59pm ET |  -0.32 / -1.01%Today’s Change | 20.24 Today|||52-Week Range 39.43 | +12.84% Year-to-Date |
Latest DNLI News | Press Releases
| Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains? Feb 03 / Zacks.com - Paid Partner Content | Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates Feb 02 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 31.70 |
| Today’s open | 31.32 |
| Day’s range | 30.78 - 31.74 |
| Volume | 10,475 |
| Average volume (3 months) | 778,373 |
| Market cap | $4.3B |
Data as of 3:59pm ET, 02/06/2023
Growth & Valuation
| Earnings growth (last year) | -466.28% |
| Earnings growth (this year) | -6.98% |
| Earnings growth (next 5 years) | -11.02% |
| Revenue growth (last year) | -85.50% |
| P/E ratio | NM |
| Price/Sales | 111.38 |
| Price/Book | 4.03 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRSPCRISPR Therapeutics ... | +0.24 | +0.43% |
| ---- | ||
| ZLABZai Lab Ltd | -1.09 | -2.72% |
| ARWRArrowhead Pharmaceut... | -3.24 | -8.82% |
Data as of 4:00pm ET, 02/06/2023
Financials
| Next reporting date | February 27, 2023 |
| EPS forecast (this quarter) | -$0.79 |
| Annual revenue (last year) | $48.7M |
| Annual profit (last year) | -$290.6M |
| Net profit margin | -597.15% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Francisco, California |
Forecasts
